【ChiCTR2000031929】Can dermatological tarcolimus 0.1 % ointment be used for treatment of spring catarrh what is its efficacy and safety profile
ChiCTR2000031929
结束
/
/
/
2020-04-15
/
/
春季角膜结膜炎
Can dermatological tarcolimus 0.1 % ointment be used for treatment of spring catarrh what is its efficacy and safety profile
Comparison of efficacy of dermatological 0.1% tacrolimus in treatment on vernal keratoconjunctivitis
52250
Tacrolimus has been used in different concentrations for ophthalmic use. It is used in 0.1 % as well as in 0.03% concentrations. Some studies claim it is more effective in 0.1 % concentration. In most studies tacrolimus is studied in bid dose, we intend to check its efficacy in HS dose.
单臂
上市后药物
N/A
N/A
No funding
/
50
/
2019-07-01
2020-03-31
/
Inclusion criteria were all the pediatric patients of severe VKC, unmanageable with conventional treatment (anti-histamines/mast cell stabilizers/NSAIDS/steroids) or patients showing recurrence after discontinuation of steroids or having steroid-induced complications.；
请登录查看Exclusion criteria were any coexisting ocular disorders such as conjunctival or corneal diseases, ocular infections, uveitis, Stevens Johnson syndrome, contact lens usage, history of ocular surgery. Informed consent was taken and all the patients were explained about the study.；
请登录查看Self-sponsored
52250
Self-sponsored的其他临床试验
- Total thyroidectomy versus Total thyroidectomy with prophylactic central compartment neck dissection in early papillary thyroid cancer
- Can dermatological tarcolimus 0.1 % ointment be used for treatment of spring catarrh what is its efficacy and safety profile
- EFFECTIVENESS OF DISTANCE INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS IN KHYBER PUKHTUNKHWA, PAKISTAN
巴基斯坦古吉兰瓦拉医学院的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04